MDD

The study, which was presented at the Meeting of the American College of Neuropsychopharmacology yesterday, found that patients using the technology improved their sustained attention compared to those in the control group. 

Otsuka intends to invest more than $300 million in an FDA-cleared software app that will apply cognitive therapy principals either with or without prescription drugs.